RC
TBPH icon

Roundview Capital’s Theravance Biopharma TBPH Stock Holding History

Roundview Capital’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-37,485
Closed -$412K – 171
2015
Q3 		$412K Sell
37,485
-2,061
-5% -$26.2K 0.18% 119
2015
Q2 		$515K Sell
39,546
-1,081
-3% -$16.8K 0.19% 109
2015
Q1 		$705K Sell
40,627
-1,290
-3% -$23.6K 0.28% 89
2014
Q4 		$625K Buy
41,917
+1,948
+5% +$33.9K 0.26% 101
2014
Q3 		$921K Sell
39,969
-142
-0.4% -$4.12K 0.41% 70
2014
Q2 		$1.28M Buy
+40,111
New +$1.21M 0.52% 69

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Roundview Capital's TBPH Position: Q4 2015 in Review

Roundview Capital sold out of Theravance Biopharma (TBPH) in Q4 2015, closing a stake of 37,485 shares — an estimated $412K sold.

Roundview Capital first reported a position in TBPH in Q2 2014 and held it in 6 quarters. The position peaked at $1.28M in Q2 2014. 83 funds tracked by Wall St. Rank hold TBPH as of Q4 2015.

  • Roundview Capital reported no remaining Theravance Biopharma position as of Q4 2015 after selling out during the quarter.
  • Roundview Capital sold 37,485 Theravance Biopharma shares in Q4 2015, an estimated $412K.
  • Roundview Capital first reported a position in Theravance Biopharma in Q2 2014 and held it in 6 quarters.
  • Roundview Capital's Theravance Biopharma position peaked at $1.28M in Q2 2014.
  • 83 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2015.

Based on Roundview Capital's 13F filing for Q4 2015, filed 11 Feb 2016.